MedTrace Logo

Omega-3 Fatty Acid in the Prevention of Migraine

NCT04572789 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2022-06-23

No results posted yet for this study

Summary

To understand the clinical efficacy for omega-3 PUFAs migraine prevention.To uncover the underlying biochemical or neurophysiological mechanisms by which omega-3 PUFAs for migraine prevention.

Conditions

  • Migraine
  • Omega-3 Polyunsaturated Fatty Acids

Interventions

DIETARY_SUPPLEMENT

Omega-3 polyunsaturated fatty acids

All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.

DIETARY_SUPPLEMENT

omega-6 PUFAs

All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.

Sponsors & Collaborators

  • Kuang Tien General Hospital

    lead OTHER

Principal Investigators

  • Chun-Pai Yang, Dr. · Neurology department of Kuang Tien General hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572789 on ClinicalTrials.gov